MedTrace Logo

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

NCT06417892 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-04-21

No results posted yet for this study

Summary

To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma that failed to be treated by anti-PD-1 /PD-L1 regimen

Conditions

Interventions

DRUG

PD-1inhibitor

PD-1 antibody was selected according to first-line drug use

DRUG

Fruquintinib

a small molecular anti-tumor angiogensis drug

DRUG

albumin paclitaxel

a kind of cytotoxic chemotherapy drug

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • LIN YANG, Doctor · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2026-05-31
Completion
2026-12-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06417892 on ClinicalTrials.gov